114 related articles for article (PubMed ID: 11425289)
1. Androgenic progestins amplify the breast cancer risk associated with hormone replacement therapy by boosting IGF-I activity.
McCarty MF
Med Hypotheses; 2001 Feb; 56(2):213-6. PubMed ID: 11425289
[TBL] [Abstract][Full Text] [Related]
2. Progestagen component in combined hormone replacement therapy in postmenopausal women and breast cancer risk: a debated clinical issue.
Gadducci A; Biglia N; Cosio S; Sismondi P; Genazzani AR
Gynecol Endocrinol; 2009 Dec; 25(12):807-15. PubMed ID: 19906000
[TBL] [Abstract][Full Text] [Related]
3. Cyproterone, norethindrone, medroxyprogesterone and levonorgestrel are less potent local human growth hormone and insulin-like growth factor I secretion stimulators than progesterone in human breast cancer explants expressing the estrogen receptor.
Milewicz T; Kolodziejczyk J; Krzysiek J; Basta A; Sztefko K; Kurek S; Stachura J; Gregoraszczuk EL
Gynecol Endocrinol; 2002 Aug; 16(4):319-29. PubMed ID: 12396561
[TBL] [Abstract][Full Text] [Related]
4. Hormone replacement therapy and risk of breast cancer: the role of progestins.
Stahlberg C; Pedersen AT; Lynge E; Ottesen B
Acta Obstet Gynecol Scand; 2003 Apr; 82(4):335-44. PubMed ID: 12716318
[TBL] [Abstract][Full Text] [Related]
5. Hormone replacement therapy use and variations in the risk of breast cancer.
Opatrny L; Dell'Aniello S; Assouline S; Suissa S
BJOG; 2008 Jan; 115(2):169-75; discussion 175. PubMed ID: 18081598
[TBL] [Abstract][Full Text] [Related]
6. Comparative cardiovascular effects of different progestins in menopause.
Rosano GM; Fini M
Int J Fertil Womens Med; 2001; 46(5):248-56. PubMed ID: 11720197
[TBL] [Abstract][Full Text] [Related]
7. Breast cancer risk in the WHI study: the problem of obesity.
Kuhl H
Maturitas; 2005 May; 51(1):83-97. PubMed ID: 15883113
[TBL] [Abstract][Full Text] [Related]
8. Hormone replacement therapy and cancer.
Gynecol Endocrinol; 2001 Dec; 15(6):453-65. PubMed ID: 11826770
[TBL] [Abstract][Full Text] [Related]
9. Controversial issues in climacteric medicine II. Hormone replacement therapy and cancer. International Menopause Society Expert Workshop. 9-12 June 2001, Opera del Duomo, Pisa, Italy.
Genazzani AR; Gadducci A; Gambacciani M
Climacteric; 2001 Sep; 4(3):181-93. PubMed ID: 11588941
[TBL] [Abstract][Full Text] [Related]
10. The effects of sex steroid replacement therapy on an expanded panel of IGF-related peptides.
Renehan AG; Frystyk J; Howell A; O'dwyer ST; Shalet SM; Flyvbjerg A
Growth Horm IGF Res; 2007 Jun; 17(3):210-9. PubMed ID: 17360217
[TBL] [Abstract][Full Text] [Related]
11. Modulation by progestogens of the effects of oestrogen on hepatic endocrine function in postmenopausal women.
Nugent AG; Leung KC; Sullivan D; Reutens AT; Ho KK
Clin Endocrinol (Oxf); 2003 Dec; 59(6):690-8. PubMed ID: 14974909
[TBL] [Abstract][Full Text] [Related]
12. The estrogenic activity of synthetic progestins used in oral contraceptives enhances fatty acid synthase-dependent breast cancer cell proliferation and survival.
Menendez JA; Oza BP; Colomer R; Lupu R
Int J Oncol; 2005 Jun; 26(6):1507-15. PubMed ID: 15870863
[TBL] [Abstract][Full Text] [Related]
13. Effects of hormone replacement therapy on insulin-like growth factor (IGF)-I, IGF-II and IGF binding protein (IGFBP)-1 to IGFBP-4: implications for cardiovascular risk.
Heald A; Kaushal K; Anderson S; Redpath M; Durrington PN; Selby PL; Gibson MJ
Gynecol Endocrinol; 2005 Mar; 20(3):176-82. PubMed ID: 16019358
[TBL] [Abstract][Full Text] [Related]
14. Progestogen use in women approaching the menopause and breast cancer risk.
Campagnoli C; Ambroggio S; Lotano MR; Peris C
Maturitas; 2009 Apr; 62(4):338-42. PubMed ID: 19118958
[TBL] [Abstract][Full Text] [Related]
15. Differential effects of various progestogens on metabolic risk factors for breast cancer.
Campagnoli C; AbbĂ C; Ambroggio S; Lotano MR; Peris C
Gynecol Endocrinol; 2007 Oct; 23 Suppl 1():22-31. PubMed ID: 17943536
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer risk with postmenopausal hormonal treatment.
Collins JA; Blake JM; Crosignani PG
Hum Reprod Update; 2005; 11(6):545-60. PubMed ID: 16150813
[TBL] [Abstract][Full Text] [Related]
17. Postmenopausal hormone therapy: cardiovascular risks.
Prescrire Int; 2003 Apr; 12(64):65-9. PubMed ID: 12674130
[TBL] [Abstract][Full Text] [Related]
18. Tamoxifen, hormone receptors and hormone replacement therapy in women previously treated for breast cancer: a cohort study.
Dew JE; Wren BG; Eden JA
Climacteric; 2002 Jun; 5(2):151-5. PubMed ID: 12051110
[TBL] [Abstract][Full Text] [Related]
19. Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in Sweden.
Olsson HL; Ingvar C; Bladström A
Cancer; 2003 Mar; 97(6):1387-92. PubMed ID: 12627501
[TBL] [Abstract][Full Text] [Related]
20. Case-control study of postmenopausal hormone replacement therapy and endometrial cancer.
Strom BL; Schinnar R; Weber AL; Bunin G; Berlin JA; Baumgarten M; DeMichele A; Rubin SC; Berlin M; Troxel AB; Rebbeck TR
Am J Epidemiol; 2006 Oct; 164(8):775-86. PubMed ID: 16997897
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]